Victoria Johnson

FDA approves the new therapy under the name Enflonsia, offering effective RSV prevention for infants during their first RSV season.

Phase 3 trials show enlicitide decanoate significantly lowers LDL cholesterol, offering a promising oral treatment for hyperlipidemia and cardiovascular risk.

Discover the latest advancements in pulmonology, including innovative treatments for asthma, COPD, and pulmonary sarcoidosis, showcased at ATS 2025.

New predictive models enhance clinical decision-making for children with pneumonia, identifying severity levels to improve treatment outcomes effectively.

The FDA approves mepolizumab as a new maintenance treatment for COPD, showing significant reduction in exacerbations for specific patients.

The approval adds to Ritestar’s currently approved albuterol sulfate 2.5 mg/3 mL (0.083%), 1.25 mg/3 mL, and 0.63 mg/3 mL strength products.

Associations were particularly strong for people with severe COPD.

Vapendavir shows promise in reducing respiratory symptoms and illness duration in COPD patients infected with rhinovirus.

Long-term studies reveal that benralizumab achieves sustained remission in severe eosinophilic asthma, significantly reducing exacerbations in older adults.

New research follows a previous landmark study that linked mucus plugs to increased mortality in people with COPD even without hallmark symptoms.

In part 2 of this episode of Crisis Point, 4 experts on pain and opioid misuse discuss continuing efforts to turn the tide.

In part 1 of this episode of Crisis Point, 4 experts on pain and opioid misuse discuss the evolving public health crisis.

New findings reveal significant systemic symptoms in pediatric patients with PR-10-related pollen food allergy syndrome, highlighting the need for better management strategies.

Explore innovative strategies for asthma management that prioritize shared decision-making and address environmental, social, and behavioral factors.

A recent study reveals that asthma-COPD overlap does not significantly worsen outcomes in well-managed severe asthma patients.

New findings reveal that higher HbA1c levels worsen asthma control in children, linking metabolic dysfunction to increased asthma morbidity.

Virtual pulmonary rehabilitation enhances access and improves outcomes for COPD patients, demonstrating safety and effectiveness in individualized care.

New triple therapy BGF shows significant and clinically meaningful lung function improvement in patients with uncontrolled asthma, with full data readouts coming soon.

The month in review spotlights new data for COPD and bronchiectasis, as well as new research and conversations around smoking.

Mepolizumab significantly reduces COPD exacerbations in patients with eosinophilic phenotype, offering new hope for improved management and patient outcomes.

The 25-mg brensocatib group showed statistically significant changes in FEV1 decline as well as pulmonary exacerbations.

In new preference research, the average participant with AA was willing to trade approximately 5 years of life to avoid impacts associated with 50–100% scalp hair loss.

The findings may facilitate accurate diagnoses, which could help patients slow or stop permanent hair loss.

Participants in the cytisinicline group also had a significantly greater reduction in smoking urges.

Overall, Asthma Control Test (ACT) measures improved by 37%.

In this summary, we highlight the latest issue of our pulmonology research quarterly newsletter powered by the American Lung Association Research Institute.

Mindy Hoang, MD, discussed Wayne State University’s program to help clinicians understand and address underserved patients’ potential social needs.